|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Jakafi
|
|
gptkbp:activities
|
Janus kinase inhibitor
|
|
gptkbp:affects
|
not fully understood
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Olumiant
|
|
gptkbp:business_model
|
important consideration.
|
|
gptkbp:class
|
immunomodulator
|
|
gptkbp:clinical_trial
|
ongoing
Phase 3
autoimmune diseases
narrow
promising
|
|
gptkbp:collaborations
|
international studies
|
|
gptkbp:combatants
|
high
|
|
gptkbp:competitors
|
high
|
|
gptkbp:contraindication
|
active infections
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:education
|
important for safety
|
|
gptkbp:effective_date
|
gptkb:2018
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:feedback
|
generally positive
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:healthcare
|
2018-06-28
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Baricitinib
|
|
gptkbp:indication
|
gptkb:COVID-19
|
|
gptkbp:ingredients
|
C16 H17 N7 O3
|
|
gptkbp:interacts_with
|
other immunosuppressants
caution with other medications
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L04 A A30
|
|
gptkbp:is_effective_against
|
improves quality of life
|
|
gptkbp:is_monitored_by
|
required during treatment
|
|
gptkbp:is_used_for
|
gptkb:rheumatoid_arthritis
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Olumiant
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
essential medicines
|
|
gptkbp:notable_work
|
effective in reducing symptoms
|
|
gptkbp:pharmacokinetics
|
absorption
inhibits JA K1 and JA K2
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
expensive
|
|
gptkbp:provides_information_on
|
updated regularly
monitor liver function
recommended for moderate to severe cases
|
|
gptkbp:publishes
|
numerous
|
|
gptkbp:receives_funding_from
|
public and private sources
|
|
gptkbp:regulatory_compliance
|
approved in multiple countries
|
|
gptkbp:research_areas
|
rheumatology
|
|
gptkbp:safety_features
|
risk of serious infections
|
|
gptkbp:sales
|
growing
|
|
gptkbp:scholarships
|
available through programs
|
|
gptkbp:side_effect
|
headache
nausea
thrombosis
increased risk of infections
increased liver enzymes
|
|
gptkbp:supply_chain
|
gptkb:launch_complex
|
|
gptkbp:treatment
|
varied
varies by patient
inhibits cytokine signaling
positive in many studies
|
|
gptkbp:type_of
|
1187594-09-7
|
|
gptkbp:type_of_care
|
important for effectiveness
|
|
gptkbp:type_of_insurance
|
coverage varies
|
|
gptkbp:updates
|
frequent
|